Clinical Research Directory

Inclusion Criteria: * Voluntarily enroll in the study, able to understand and voluntarily sign the informed consent form; * Aged 18-65 years (inclusive), no gender restriction; * A history of HBsAg positivity for at least 6 months or other evidence suggesting chronic hepatitis B; * First observed clinical cure after treatment with peginterferon α-2b (PegIntron®), either as monotherapy or in combination with NAs, defined as serum HBsAg negative (\<0.05IU/ml), HBV DNA undetectable (HBV DNA\<20IU/ml), and HBeAg negative, within a 4-week window from the first observed day of clinical cure at the time of screening; * Agreement to undergo two liver biopsies during the study; * Negative pregnancy test within 24 hours before the first liver biopsy (for childbearing-age females); and subjects (both male and female) should use effective contraception during the study period. Exclusion Criteria: * Lactating women; * Evidence of acute severe liver injury: such as ALT \> 10 ULN, or significantly elevated ALT with significantly elevated bilirubin; * Evidence of decompensated liver disease: such as ascites, esophageal varices rupture bleeding, sepsis, hepatic encephalopathy, hepatorenal syndrome, etc.; or history of decompensated cirrhosis; * Evidence of hepatocellular carcinoma; * Prothrombin time (PT) or INR \> ULN; * Participation in other interventional trial studies within 3 months before screening or other conditions deemed unsuitable for inclusion by the investigator.